133240-26-3 Usage
Uses
Used in Organic Synthesis:
Methyl 4'-bromomethylbiphenyl-2-carboxylate is used as a reagent and building block in organic synthesis for the production of various organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Methyl 4'-bromomethylbiphenyl-2-carboxylate is used as a key intermediate in the synthesis of pharmaceutical compounds. Its versatile chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 4'-bromomethylbiphenyl-2-carboxylate is utilized in the agrochemical industry for the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features contribute to the development of effective and targeted agrochemical products.
Used in Material Science:
In the field of material science, Methyl 4'-bromomethylbiphenyl-2-carboxylate is employed in the development of advanced materials with specific properties. Its chemical structure and reactivity enable the creation of materials with tailored characteristics for various applications.
Safety Precautions:
It is crucial to handle Methyl 4'-bromomethylbiphenyl-2-carboxylate with care and follow proper safety guidelines to minimize potential hazards and risks to human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 133240-26-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,2,4 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 133240-26:
(8*1)+(7*3)+(6*3)+(5*2)+(4*4)+(3*0)+(2*2)+(1*6)=83
83 % 10 = 3
So 133240-26-3 is a valid CAS Registry Number.
133240-26-3Relevant academic research and scientific papers
COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
-
, (2016/12/22)
The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical
Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development
Dodo, Kosuke,Aoyama, Atsushi,Noguchi-Yachide, Tomomi,Makishima, Makoto,Miyachi, Hiroyuki,Hashimoto, Yuichi
, p. 4272 - 4285 (2008/09/21)
Liver X receptors (LXR), which were originally reported as oxysterol-activated nuclear receptors, were recently found to recognize glucose as a physiological ligand. On this basis, we have already developed novel LXR antagonists based upon α-glucosidase i
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
-
, (2008/06/13)
Substituted Imidazo-fused 6-membered heterocycles of structural formula: STR1 wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.
SUBSTITUTED IMIDAZO-FUSED 6-MEMBERED HETEROCYCLCES AS ANGIOTENSIN II ANTAGONISTS
-
, (2008/06/13)
Substituted Imidazo-fused 6-membered heterocycles of structural formula: STR1 wherein A, B, C, and D are independently carbon atoms or nitrogren atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.
